Mayo Foundation for Medical Education and Research

University of California

Euroimmun Medizinische Labordiagnostika Ag

Cz Biohub Sf, Llc.

Andrew McKeon

Vanda A Lennon

Thomas J Kryzer

Sean J Pittock

Shannon Hinson

Boyan Fang

Josephe A Honorat

Lars Komorowski

Yvonne Denno

Ramona Miske

Madeleine Scharf

Joseph L DeRisi

Christiane Radzimski

Stefanie Hahn

Mandy Unger

Caleigh Mandel-Brehm

Michael R Wilson

Brian O'Donovan

Divyanshu Dubey

Avi Gadoth

James P Fryer

This disclosure describes methods and compositions for detecting the presence of a Kelch-like protein 11 autoantibody in a biological sample. Also provided are methods of treating subjects with testicular cancer or a premalignant condition and paraneoplastic encephalomyelitis.

Autoantibodies as biomarker of paraneoplastic encephalitis associated with testicular cancer

This document provides methods and materials involved in identifying and treating autoimmune GFAP (glial fibrillary acidic protein) astrocytopathy, a novel meningoencephalomyelitis, in humans as well as methods and materials for identifying and offering early treatment for patients having autoimmune GFAP astrocytopathy whose autoantibody profile predicts a high likelihood of having underlying cancer (e.g., adenocarcinoma or teratoma).

Methods and materials for identifying and treating autoimmune GFAP astrocytopathy

A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.

Autoantibodies to Septin-7 and diagnosis of neurological disease

Methods and materials herein are useful for assessing and/or treating autoimmune ataxias associated with septin-specific autoantibodies (e.g., septin-5-specific autoantibodies). For example, septin-5 polypeptides are provided as well as methods for using septin-5 polypeptides to detect septin-5-specific autoantibodies and/or to treat a mammal having an autoimmune ataxia.

Assessing and treating autoimmune ataxia

This document provides methods and materials for detecting PCA-2-specific autoantibodies, which can be associated with paraneoplastic neurological disorders and cancers associated with PCA-2-specific autoantibodies.

Materials and methods for evaluating and treating cancer

Growing community of inventors

Rochester, MN, United States of America

Andrew McKeon